J&J To Power Ahead With 10 Launches In Four Years
Set To Outpace Sector Again
Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further.
You may also be interested in...
A strong fourth quarter and full-year 2019 performance by J&J was driven by significant sales growth for Tremfya and Stelara. CFO Wolk said a $4bn opioids settlement remains on track.
Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.